INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Picard Medical, Inc. of Class Action Lawsuit and Upcoming Deadlines - PMI [Accessibility Statement] Skip NavigationNEW YORK, Feb. 12, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Picard Medical, Inc. ("Picard" or the "Company") (NYSE: PMI). Such investors are advised to contact Danielle Peyton at [[email protected]] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 798 ...

Core Viewpoint - A class action lawsuit has been filed against Richtech Robotics Inc. for alleged securities fraud and unlawful business practices, following a report that questioned the company's claims about its partnership with Microsoft [1]. Group 1: Lawsuit Details - The class action lawsuit is focused on whether Richtech and its officers engaged in securities fraud or other unlawful business practices [1]. - Investors who purchased Richtech securities during the Class Period have until April 3, 2026, to apply to be appointed as Lead Plaintiff [1]. Group 2: Allegations and Impact - A report by Hunterbrook Media alleged that Richtech mischaracterized its relationship with Microsoft, claiming a "close collaboration" when it was merely a standard customer program without commercial elements [1]. - Following the report, Richtech's stock price dropped by $1.06 per share, or 20.87%, closing at $4.02 per share on January 29, 2026 [1]. Group 3: Company Background - Pomerantz LLP, the law firm handling the case, is recognized for its expertise in corporate, securities, and antitrust class litigation, having recovered numerous multimillion-dollar damages awards for class members [1].

Core Viewpoint - A class action lawsuit has been filed against Oracle Corporation, alleging securities fraud and unlawful business practices related to its AI infrastructure strategy and financial disclosures [1]. Summary by Relevant Sections Class Action Details - Investors who suffered losses in Oracle securities are encouraged to contact Pomerantz LLP to join the class action, with a deadline to apply as Lead Plaintiff by April 6, 2026 [1]. - The lawsuit claims that Oracle and its executives made misleading statements regarding the company's capital expenditures and revenue growth expectations [1]. Allegations of Misleading Statements - The complaint alleges that Oracle's AI infrastructure strategy would lead to significant increases in capital expenditures without corresponding near-term revenue growth [1]. - It is claimed that Oracle's increased spending poses risks to its debt, credit rating, free cash flow, and project funding capabilities [1]. Impact of Analyst Reports - On September 24, 2025, S&P Global Ratings indicated that OpenAI could account for over one-third of Oracle's total revenues by fiscal 2028, raising concerns about OpenAI's ability to meet contractual obligations [1]. - Following a "Sell" rating from Rothschild & Co. Redburn on September 25, 2025, Oracle's stock price fell over 5%, with a price target set at $175, indicating a potential 40% decline [1]. Financial Performance and Stock Reactions - Oracle's Q2 fiscal year 2026 results showed revenue growth below analyst expectations, with capital expenditures exceeding estimates and negative free cash flow exceeding $10 billion, leading to an 11% drop in stock price [1]. - Reports on December 12, 2025, indicated delays in data center completion for OpenAI, further suggesting potential revenue growth delays, which contributed to additional stock price declines [1]. - On December 17, 2025, it was reported that Blue Owl Capital withdrew funding for a $10 billion data center project due to concerns over Oracle's spending and rising debt, resulting in a further 5% drop in stock price [1].

Core Viewpoint - A class action lawsuit has been filed against Masonite International Corporation, alleging securities fraud and unlawful business practices related to the company's stock repurchase activities during a specific period [1]. Group 1: Lawsuit Details - The lawsuit claims that Masonite and its officers/directors failed to disclose multiple formal acquisition offers from Owens Corning to purchase all outstanding shares of Masonite at prices significantly above the market prices during the stock repurchase period [1]. - Investors who sold Masonite common stock during the Class Period have until April 7, 2026, to request to be appointed as Lead Plaintiff in the class action [1]. Group 2: Company Background - Pomerantz LLP, the law firm handling the case, is recognized for its expertise in corporate, securities, and antitrust class litigation, having a history of recovering multimillion-dollar damages for victims of securities fraud [1].

Core Viewpoint - A class action lawsuit has been filed against Paysafe Limited due to allegations of securities fraud and unlawful business practices, following disappointing financial results and a significant stock price drop [1]. Financial Performance - Paysafe reported third-quarter 2025 revenue of $433.8 million, missing consensus estimates by $5.8 million [1]. - The company experienced a net loss of $87.7 million, a substantial increase from a net loss of $12.98 million in the same period the previous year [1]. - Full-year 2025 expected revenue has been revised down to $17 million at the midpoint, with adjusted EPS projected at $0.50 [1]. Management Commentary - CEO Bruce Lowthers indicated that a last-minute client shutdown led to several million-dollar write-downs in Q3 [1]. - The company is facing challenges in a lower-tier market, particularly with high-risk Merchant Category Codes (MCC), which are difficult for banks to underwrite [1]. - Lowthers acknowledged ongoing difficulties with certain MCC codes and the company's efforts to navigate these challenges [1]. Stock Market Reaction - Following the announcement of the financial results, Paysafe's stock price fell by $2.80 per share, or 27.6%, closing at $7.36 per share on November 13, 2025 [1].

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ramaco Resources, Inc. of Class Action Lawsuit and Upcoming Deadlines - METC [Accessibility Statement] Skip NavigationNEW YORK, Feb. 12, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Ramaco Resources, Inc. ("Ramaco" or the "Company") (NASDAQ: METC). Such investors are advised to contact Danielle Peyton at [[email protected]] or 646-581-9980, (or 888.4-POMLAW), toll-free, ...

Core Viewpoint - A class action lawsuit has been filed against PomDoctor Ltd. for alleged securities fraud and unlawful business practices, with a significant drop in share price following a promotional scheme [1] Group 1: Class Action Lawsuit Details - The lawsuit is focused on whether PomDoctor and its officers engaged in securities fraud [1] - Investors have until April 6, 2026, to apply as Lead Plaintiff if they purchased PomDoctor securities during the Class Period [1] Group 2: Share Price Movement - PomDoctor's share price increased from $4.00 to an all-time high of $6.09 before crashing by approximately 91% to $0.50 on December 10, 2025 [1] - The price surge occurred without any fundamental news from the company, raising concerns about the legitimacy of the increase [1] Group 3: Allegations of Fraud - Investigations revealed that PomDoctor allegedly used social media for a "pump and dump" scheme, misleading investors through impersonation and baseless claims [1] - The promotional activities created a buying frenzy among retail investors, leading to significant financial losses [1]

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in China Liberal Education Holdings Limited of Class Action Lawsuit and Upcoming Deadlines - CLEUF [Accessibility Statement] Skip NavigationNEW YORK, Feb. 12, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against China Liberal Education Holdings Limited ("CLEU" or the "Company") (OTCMKTS: CLEUF). Such investors are advised to contact Danielle Peyton at [[email protected]] or 646-581 ...

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ultragenyx Pharmaceutical Inc. of Class Action Lawsuit and Upcoming Deadlines - RARE [Accessibility Statement] Skip NavigationNEW YORK, Feb. 12, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or the "Company") (NASDAQ: RARE). Such investors are advised to contact Danielle Peyton at [[email protected]] or 646-581-9980, (or 888.4- ...

Core Viewpoint - A securities class action lawsuit has been filed against Varonis Systems, Inc. and its executives, with a lead plaintiff deadline approaching on March 9, 2026, focusing on allegations of concealed issues in the company's transition to a Software-as-a-Service (SaaS) model [1][4]. Group 1: Allegations and Lawsuit Details - The lawsuit claims that Varonis executives failed to disclose significant renewal challenges in its Federal vertical and legacy on-premises business while promoting a smooth transition to SaaS [2][5]. - Following a disclosure on October 28, 2025, regarding difficulties in converting existing customers to the SaaS model, Varonis reported a 63.9% year-over-year decline in term license revenue and reduced its Annual Recurring Revenue (ARR) outlook, leading to a 48% drop in stock price, equating to a loss of approximately $3.8 billion in market value [3][9]. Group 2: Company Performance and Market Reaction - The lawsuit highlights a discrepancy between Varonis's optimistic statements about its SaaS transition and the actual struggles faced in its Federal renewal cycle and on-premises subscription business [5][9]. - After the Q3 performance miss, Varonis significantly reduced its Q4 revenue and full-year ARR guidance, which contributed to the sharp decline in stock value from $63.00 to $32.34 in a single day [9].